![Pamela Strode](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Storia della carriera di Pamela Strode
Precedenti posizioni note di Pamela Strode
Società | Posizione | Inizio | Fine |
---|---|---|---|
EPIZYME, INC. | Consigliere Generale | 29/09/2016 | 01/08/2019 |
FULCRUM THERAPEUTICS, INC. | Consigliere Generale | 05/09/2019 | - |
Cerulean Pharma, Inc.
![]() Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Consigliere Generale | 06/10/2014 | - |
Formazione di Pamela Strode
Rutgers State University of New Jersey | Undergraduate Degree |
Temple University (Pennsylvania) | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Posizioni
General Counsel | 3 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
FULCRUM THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Cerulean Pharma, Inc.
![]() Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Health Technology |
Epizyme, Inc.
![]() Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Pamela Strode
- Esperienza